HIL Serum Indices
[HIL Serum Indices]
EPTIS Ringversuch Nr. 1177186 | Letze Änderung 2024-09-24 | URL: https://www.eptis.bam.de/pts1177186 https://www.eptis.bam.de/pts1177186
| Name des Anbieters | ||||||||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||
| Sprache(n) | ||||||||||||||||||||||
| Anmerkungen | Most manufacturers now include Haemolytic / Icteric / Lipaemic (HIL) Indices as part of their testing repertoire as a means of identifying these interfering parameters. The three major sample interferences found to affect the accuracy and reliability of most laboratory results are haemoglobin, lipaemia and Icterus. The aim of the Weqas HIL Serum Indices programme is to assess: the ability of the analysers HIL indices test to identify the presence of these potential interference, to determine how laboratories deal with results where indices suggest that interferences are present and to promote the harmonisation of reporting. The programme provides 3 monthly samples containing either no interferant, bilirubin, haemoglobin, intralipid (surrogate marker of turbidity) or a mix of interferants at a range of concentrations. A batch is prepared every 6 months consisting of 14 serum pools: 3 haemolysed, 3 icteric, 3 intralipid, 4 mixed and 1 negative. A total of 18 samples are dispatched every 6 months, with some pools dispatched on more than one occasion. The target value is assigned from the calculated gravimetric addition of the interferant, supported by the quantitative analysis of bilirubin, haemoglobin and triglyceride (as an approximate verification of the concentration of intralipid). Both semi-quantitative and qualitative results are accommodated. Key Features: - Liquid stable samples are supplied ready to use; no pre-analytical preparation is required. - Quantitative and qualitative reporting available. - Full range of HIL indices covered; samples with individual and combined indices distributed to assess potential interferences. For more information: https://www.weqas.com/services/eqa/serum-indices/ or contact@weqas.com | |||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||
|
||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||
| Zielgruppe des Ringversuchs | The clinical usefulness of laboratory test results depends on performance evaluation and detection of errors including those that affect the integrity of the sample and presence of interferants in that sample. | |||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | |||||||||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 nicht für alle Parameter |
|||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 1.0mL. ) | |||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2016 | |||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.